FDA approves first claudin-18.2-targeted antibody for gastric cancer

被引：0
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2024年 / 23卷 / 12期
关键词：
D O I：
10.1038/d41573-024-00172-7
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：884 / 884
页数：1
相关论文
共 50 条
  • [41] Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer
    Jin, Wu-mei
    Zhu, Yan
    Cai, Zhi-qiang
    He, Na
    Yu, Zhi-qiong
    Li, Shuang
    Yang, Ji-yuan
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (07) : 2631 - 2647
  • [42] Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
    Ungureanu, Bogdan Silviu
    Lungulescu, Cristian-Virgil
    Pirici, Daniel
    Turcu-Stiolica, Adina
    Gheonea, Dan Ionut
    Sacerdotianu, Victor Mihai
    Liliac, Ilona Mihaela
    Moraru, Emil
    Bende, Felix
    Saftoiu, Adrian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] FDA approves first anti-TFPI antibody for haemophilia A and B
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (12) : 884 - 884
  • [44] Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?
    Mathias-Machado, Maria Cecilia
    de Jesus, Victor Hugo Fonseca
    Jacome, Alexandre
    Donadio, Mauro Daniel
    Aruquipa, Marcelo Porfirio Sunagua
    Fogacci, Joao
    Cunha, Renato Guerino
    da Silva, Leonard Medeiros
    Peixoto, Renata D'Alpino
    CANCERS, 2024, 16 (03)
  • [45] FDA approves first-in-class cancer metabolism drug
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (09) : 593 - 593
  • [46] Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
    Kim, Hyung-Don
    Choi, Eugene
    Shin, Jinho
    Lee, In-Seob
    Ko, Chang Seok
    Ryu, Min-Hee
    Park, Young Soo
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [47] FDA approves first-in-class cancer metabolism drug
    Asher Mullard
    Nature Reviews Drug Discovery, 2017, 16 : 593 - 593
  • [48] Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
    Hyung-Don Kim
    Eugene Choi
    Jinho Shin
    In-Seob Lee
    Chang Seok Ko
    Min-Hee Ryu
    Young Soo Park
    Scientific Reports, 13
  • [49] Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy
    Pandian, Swarna
    Li, Zusheng
    Chan, Eugene
    Markelewicz, Robert
    Wyant, Timothy
    Lakshmikanthan, Sribalaji
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [50] Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer
    Weng, Weiwei
    Zhang, Meng
    Ni, Shujuan
    Tan, Cong
    Xu, Midie
    Wang, Xin
    Sun, Hui
    Wang, Lei
    Huang, Dan
    Sheng, Weiqi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1035 - +
12345